

From: Liverpool-ECMC
Sent: 01 June 2020 15:57
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter June 2020

[View this email in your browser](#)

LIVERPOOL ECMC NEWSLETTER JUNE 2020

COVID-19 TRIAL RE-START

The ECMC and Clatterbridge Cancer R&I team are currently reviewing all studies in line with the patient need and NIHR RE-START guidelines.

Decisions on re-starting across the ECMC portfolio will be dependent on the following criteria; Sponsor approval, Patient need, Patient safety and Staff Capacity. This programme of re-starting will be ongoing for the next few months.



**RAGNAR -
42756493CAN2002**

The RAGNAR study was opened as part of the Liverpool ECMC portfolio in February 2020 at Clatterbridge. The Liverpool ECMC team are currently the highest recruiters in the UK. We are also the first centre globally to recruit a CNS glioblastoma patient.

More information about the RAGNAR study can be found [here](#).

CCP-CANCER




Members of the Liverpool ECMC team have been re-deployed to support the UK Clinical Characterisation protocol, part of ISARIC-4C (The International Severe Acute Respiratory and Emerging Infection Consortium Coronavirus Clinical Characterisation Consortium). This is a global consortium of networks that exists to rapidly respond to and contribute to the characterisation of emerging infections.

This study is collecting samples from COVID patients to answer vital questions such as: how long are people infectious for? What are the risk factors for developing severe COVID and who might benefit from early drug treatment?

Professor Carlo Palmieri and Dr Lance Turtle in Liverpool are leading the cancer companion study to CCP-UK (led by Calum Semple (Liverpool), Kenny Baillie (Edinburgh) and Peter Openshaw (Imperial College London), which will provide data on outcomes for people with a cancer diagnosis who contract COVID, supported by several members of the Liverpool ECMC.

This study will provide vital information to help inform how cancer services can be safely delivered whilst COVID-19 remains prevalent in the community. To date over 2500 people with a cancer diagnosis have been recruited to CCP-UK. The results of this study are directly informing the Government via the SAGE committee. Several sites across the ECMC Network have expressed interest in taking part in this study.

More information about ISARIC-4C can be found [here](#).



DIS-COV-ER

The Liverpool ECMC is also supporting Dis-CoV-er, a non-randomised cohort study during the SARS-CoV-2 pandemic to understanding viral exposure and handling by cancer patients. Dis-CoV-er is led by Prof Nagesh Kalakonda.

This observational cohort study aims to systematically collect and biobank

samples from consecutive cancer patients attending hospitals in a tertiary care setting in whom the SARS-CoV-2 exposure status is unknown or negative.

The objectives of this study are to:

- To establish SARS-CoV-2 viral infection rates in patients with cancer attending hospital for cancer/treatments
- To determine seroconversion rates (SARS-CoV-2 antibody +ve vs -ve), at baseline and follow-up, within the cohort. To establish rates of new infection/re-infection in uninfected (SARS-CoV-2 PCR-ve; Ab-ve or +ve at baseline and follow-up).
- To understand the proportion of infected cancer patients who remain infected, clear the virus and/or sustain an antibody response at follow-up and then identify clinical and biological variables that correlate with these different outcomes.
- To identify clinical and biological variables of the different outcomes that correlate with SARSCoV-2 acquisition, susceptibility, immune protection, and disease severity.
- To provide information on background immune function and host-virus interactions, antibodies against other common viruses and bacteria, especially those targeted by vaccination strategies (Pneumococcal, Haemophilus, Influenza), will be measured.

EVENTS & JOB OPPORTUNITIES

There are currently no upcoming events / job opportunities within the Liverpool ECMC.

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via [e-mail](#).

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk